Skip to content


BMC Proceedings

Open Access

Identification of a common deletion region in 10q26 associated with human gliomas

  • Margarida Alves1, 2,
  • Paulo Liberato1,
  • Ana Rita Conde1, 2,
  • Manuela Mafra3,
  • Alexandra Inverno4,
  • Ana Teresa Maia5,
  • Denise Bagrel6,
  • Isabel Carreira2, 7,
  • Miguel Brito8 and
  • Carolino Monteiro1, 2Email author
BMC Proceedings20104(Suppl 2):P62

Published: 24 September 2010


MeningiomaAstrocytomaGlioblastoma MultiformeHuman GliomaOligodendrogliomas

Gliomas are the most frequent primary tumours of the central nervous system and several types of gliomas are histopathologically recognized. Loss of the whole chromosome 10, or part of it, is the most prevalent genetic abnormality in astrocytic tumours, particularly in glioblastomas, in which it is observed in up to 80% of all cases [1]. In an attempt to localize a common region of loss in these tumours, we carried out an allelotyping analysis of 25 glioblastomas multiforme, 6 astrocytomas, 4 oligodendrogliomas and 2 ependymomas using highly polymorphic DNA markers, located in the q26 region of chromosome 10. Two meningioma samples have also been analysed. Loss of heterozygosity was found in 76% (19/25) of the glioblastomas, 50% (3/6) of the astrocytomas, 50% (2/4) of the oligodendrogliomas and 100% (2/2) of the ependymomas. None of the two meningiomas showed evidence of loss in this region. The allelotyping results revealed a minimal common region of loss, bordered by the D10S1236 and D10S186 markers, spanning 8.88 Mb, which may be a possible location for a tumour suppressor gene involved in human glioma progression. This region may also be associated to glioma tumorigenesis, since it also appears deleted in early stage gliomas. The fact that microsatellite instability (MSI) screening of gliomas has rendered only one positive sample shows that there is little evidence of MSI for one of the analysed markers, suggesting that this is not a significant event in the tumorigenesis of these malignancies.

Authors’ Affiliations

Faculdade de Farmácia Universidade de Lisboa, Lisboa, Portugal
CIMAGO, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal
Hospital de São José CHLC, Serviço de Anatomia Patológica, Lisboa, Portugal
INFARMED, I.P., Parque de Saúde de Lisboa, Lisboa, Portugal
Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Cambridge, Reino Unido
Laboratoire d’Ingénierie Moléculaire et Biochimie Pharmacologique, Université Paul Verlaine, Metz, França
Faculdade de Medicina da Universidade de Coimbra, Laboratório de Citogenética, Instituto de Biologia Médica, Coimbra, Portugal
Escola Superior de Tecnologia da Saúde de Lisboa, Lisboa, Portugal


  1. Arslantas A, Artan S, Oner U, Müslümanoglu MH, Ozdemir M, Durmaz R, Arslantas D, Vural M, Cosan E, Atasoy MA: Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res. 2007, 13: 39-46. 10.1007/BF02893439.View ArticlePubMedGoogle Scholar


© Monteiro et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.